Novel small molecules potentiate premature termination codon readthrough by aminoglycosides

Area of Science:

• Genetics
• Pharmacology
• Molecular Biology

Background:

• Nonsense mutations, causing premature stop codons, are responsible for 11% of genetic diseases.
• Aminoglycosides can promote readthrough of these codons but with limited efficiency.

Purpose of the Study:

• To identify compounds that enhance aminoglycoside-induced nonsense mutation readthrough.
• To develop a potent therapeutic strategy for genetic diseases stemming from nonsense mutations.

Main Methods:

• High-throughput screening in yeast to identify readthrough-potentiating compounds.
• Chemical optimization of lead compounds, resulting in phthalimide derivative CDX5-1.
• Testing CDX5-1 in combination with aminoglycoside G418 in human cancer cell lines and patient-derived cells.

Main Results:

• CDX5-1 significantly potentiated G418-induced readthrough (up to 180-fold) in TP53 nonsense mutant cancer cells.
• The combination therapy demonstrated efficacy across multiple TP53 nonsense alleles.
• Readthrough was also successfully enhanced in patient cells with nonsense mutations in CLN2, SMARCAL1, and DMD genes.

Conclusions:

• Phthalimide derivative CDX5-1, in combination with aminoglycosides, is a potent enhancer of nonsense mutation readthrough.
• This combination therapy shows promise for treating a wide range of genetic disorders caused by various nonsense mutations.
• The findings open avenues for developing novel treatments for genetic diseases previously considered intractable.